Create a free Cannabis Equipment News account to continue

A2W Opens New Pharmaceutical Facility in Malta

Parent company ABA Chemicals Corp said it has invested more than €6 million through Amino Chemicals to address demand for EU-GMP certified extracts.

Amino, also based in Malta, has 30 years of experience developing pharmaceutical APIs.
Amino, also based in Malta, has 30 years of experience developing pharmaceutical APIs.
iStock

A2W Pharma, a pharmaceutical company based in Malta, is opening a new facility in Malta.

A2W provides full processing from raw material to bottling with chemical and stability testing capabilities. The company has begun validating materials and methods, and is expecting to receive its EU-GMP certification this summer. Its long-term vision centers around the development of botanical active substances for pharmaceutical and nutraceutical product development.

“The opening of A2W Pharma is part of our strategic vision to extend the capabilities of our operations in Malta to support our partners in the development of pharmaceutical formulations,” said Amino Chemicals CEO Antonio Sommei.

Parent company ABA Chemicals Corp said it has invested more than €6 million through Amino Chemicals to address demand for EU-GMP certified extracts. Amino, also based in Malta, has 30 years of experience developing pharmaceutical APIs and lends its commercial and regulatory expertise.

“The discoveries related to the active substances found in the cannabis plant, and their therapeutic effects, represent a shift in the way patients suffering from various ailments can be treated. A2W’s vision is to increase access to these substances, whilst utilizing 30 years of experience in pharmaceutical development to ensure adherence to the strictest of regulatory requirements,” said Tony Cai, ABA Chemicals Chairperson.

A2W’s strategy centers around developing pharmaceutical products for therapeutic areas where there is a critical need to advance patient care. The medical cannabis industry is expected to continue its growth as more countries legalize prescription use to treat neurological and immunological conditions. Industry growth can be attributed to physician education and patient awareness regarding the benefits of medical cannabis.

“We are fortunate to have the support and expertise of ABA and Amino to help us achieve our goal of entering this new sector of pharmaceutical development, which we aim to enhance with our experience and capabilities,” said Peter Paul Farrugia, A2W Pharma Director.

More in Manufacturing